



Torsten Pietsch

Kontakt

Torsten Pietsch

Publikationen (8)

Fröhlich A, Ring S, Golletz C, Pietsch T, Strieth S, Brossart P, Gielen G, Kristiansen G, Bootz F, Landsberg J, Flatz L, Hoffmann F, Sirokay J, Fietz S, Vogt T, Dietrich J, Zarbl R, Florin M, Kuster P, Saavedra G, Valladolid S, Dietrich D. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. *EBioMedicine* 2020; 59:102962.

Hoffmann F, Landsberg J, Kristiansen G, Flatz L, Pietsch T, Dietrich J, Ring S, Gielen G, Strieth S, Kuster P, Saavedra G, Brossart P, Holderried T, Posch C, Fröhlich A, Sirokay J, Niebel D, Zarbl R, Dietrich D. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. *Clin Epigenetics* 2020; 12:94.

Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet* 2019; 393:678–688.

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro Oncol* 2018; 20:400–410.

Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. *J Clin Oncol* 2016; 34:1611–9.

Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. *Neurology* 2015; 84:1242–8.

Müller K, Fleischhack G, Kortmann R, Rutkowski S, Bode U, von Bueren A, von Hoff K, Pietsch T, Warmuth-Metz M, Henke G, Budach W, Christiansen H, Zimmermann M, Siegler N, Zwiener I, Mynarek M, Tippelt S. Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies. *Int J Radiat Oncol Biol Phys* 2014; 88:1019–24.

Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol* 2010; 11:1036–47.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch